Immunome’s (IMNM) “Outperform” Rating Reaffirmed at Wedbush

Wedbush restated their outperform rating on shares of Immunome (NASDAQ:IMNM) in a research report sent to investors on Monday,RTT News reports. The brokerage currently has a $33.00 price objective on the stock.

Separately, Piper Sandler reduced their target price on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating for the company in a research note on Thursday, November 14th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Immunome currently has a consensus rating of “Buy” and a consensus target price of $28.60.

Immunome Stock Performance

Shares of IMNM opened at $8.85 on Monday. The firm’s 50 day moving average price is $10.13 and its two-hundred day moving average price is $11.94. Immunome has a twelve month low of $8.51 and a twelve month high of $26.70. The firm has a market cap of $706.03 million, a P/E ratio of -1.09 and a beta of 1.93.

Insider Transactions at Immunome

In related news, CEO Clay B. Siegall bought 150,000 shares of the stock in a transaction that occurred on Friday, January 31st. The shares were acquired at an average price of $7.75 per share, with a total value of $1,162,500.00. Following the completion of the transaction, the chief executive officer now owns 669,636 shares in the company, valued at $5,189,679. The trade was a 28.87 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 8.60% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets bought a new stake in shares of Immunome during the 4th quarter worth approximately $70,000. KLP Kapitalforvaltning AS acquired a new position in Immunome during the fourth quarter worth $75,000. AlphaQuest LLC increased its holdings in Immunome by 786,700.0% during the fourth quarter. AlphaQuest LLC now owns 7,868 shares of the company’s stock worth $84,000 after buying an additional 7,867 shares during the last quarter. Tower Research Capital LLC TRC raised its position in Immunome by 482.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company’s stock worth $91,000 after acquiring an additional 7,129 shares in the last quarter. Finally, Aquatic Capital Management LLC acquired a new stake in Immunome in the fourth quarter valued at $95,000. 44.58% of the stock is owned by institutional investors and hedge funds.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.